IN THE CLAIMS:

Please amend the claims as follows:

Cancel claims 40, 41, 45 and 46 without prejudice.

Replace claims 1, 4, 6, 8, 9, 21-24, 36, 44, 47-54, and 57 with the following amended claims:

B1

1. (Twice amended) A molecule comprising SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, which molecule (a) binds CD40, and (b) comprises a human immunoglobulin constant domain.

B2

4. (Amended) A molecule comprising SEQ ID NO:8, SEQ ID NO:9, and SEQ ID NO:10, which molecule (a) binds CD40, and (b) is a fusion protein comprising the amino acid sequence of a second molecule that is not an antibody.

B3

6. (Amended) The molecule of claim 1 which is an antibody comprising a variable domain of monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, and a human immunoglobulin constant region.

B4

8. (Twice amended) A protein comprising an amino acid sequence that has at least 95% identity to SEQ ID NO:7 as determined by use of the BLASTp computer program, which protein (a) binds CD40; and (b) comprises a human immunoglobulin constant domain.

9. (Twice amended) A protein, which protein (a) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, (b) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%, and (c) comprises human immunoglobulin constant domain.

B5

21. (Twice amended) A pharmaceutical composition comprising:

(a) a molecule comprising SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 or SEQ ID NO:10, which molecule (i) binds CD40, (ii) increases the binding of CD40

ligand to cell surface CD40 on B cells by at least 45%, and (iii) comprises a human immunoglobulin constant domain, in an amount effective for the treatment or prevention of cancer; and

(b) a pharmaceutically acceptable carrier.

22. (Twice amended) A pharmaceutical composition comprising:

(a) a protein, which protein (i) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, (ii) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%, and (iii) comprises a human immunoglobulin constant domain, in an amount effective for the treatment or prevention of cancer; and

(b) a pharmaceutically acceptable carrier.

23. (Twice amended) A pharmaceutical composition comprising:

(a) a molecule comprising SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10, which molecule (i) binds CD40, (ii) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%, and (iii) comprises a human immunoglobulin constant domain, in an amount effective for activating or augmenting an immune response; and

(b) a pharmaceutically acceptable carrier.

24. (Twice amended) A pharmaceutical composition comprising:

(a) a protein, which protein (i) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110, (ii) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%, and (iii) comprises a human immunoglobulin constant domain, in an amount effective for activating or augmenting an immune response; and

(b) a pharmaceutically acceptable carrier.

36. (Twice amended) A pharmaceutical composition comprising in an amount effective for the treatment or prevention of cancer or an immune disorder, or for activating or augmenting an immune response: (a) a molecule that binds CD40, which molecule increases the binding of CD40 ligand to cell surface CD40 on B cells; (b) CD40 ligand; and (c) a pharmaceutically acceptable carrier.

B6

44. (Amended) A protein comprising an amino acid sequence that comprises regions having at least 80% identity to SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, respectively, as determined by use of the BLASTp computer program, which protein (a) binds CD40; and (b) comprises a human immunoglobulin constant domain.

B7

47. (Amended) The molecule of claim 1, 2, 3, 4, 5, or 6, which increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%.

48. (Amended) The molecule of claim 1, 2, 3, 4, 5, or 6, which increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 50%.

49. (Amended) The molecule of claim 1, 2, 3, 4, 5, or 6, which increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 60%.

B8

50. (Amended) The molecule of claim 1, 2, 3, 4, 5, or 6, which increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 65%.

51. (Amended) The protein of claim 8, which increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%.

52. (Amended) The protein of claim 8 or 9, which increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 50%.

53. (Amended) The protein of claim 8 or 9, which increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 60%.

B8

54. (Amended) The protein of claim 8 or 9, which increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 65%.

B9

57. (Amended) The protein of claim 8, 9, or 44 which is purified.

Please add the following new claims:

69. (New) A molecule that (a) binds to CD40; (b) increases the binding of CD40 ligand to cell surface CD40 on B cells by at least 45%; and (c) comprises a human immunoglobulin constant domain.

SEQ

70. (New) The molecule of claim 69 which is a protein.

B10

71. (New) The molecule of claim 70 which is an antibody.

72. (New) The molecule of any one of claims 1-3 and 69 which is conjugated to a chemotherapeutic agent.

73. (New) The protein of any one of claims 8, 9, and 44 which is conjugated to a chemotherapeutic agent.

74. (New) The protein of claim 44 which is an antibody.

75. (New) The molecule of claim 44 which comprises SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.

76. (New) The molecule of claim 44 which comprises at least 2 CDR sequences selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO 10.

77. (New) The pharmaceutical composition of claim 21 or 23 in which the molecule is conjugated to a chemotherapeutic agent.

78. (New) The pharmaceutical composition of claim 22 or 24 in which the protein is conjugated to a chemotherapeutic agent.

79. (New) The molecule of claim 72 which is an antibody.

80. (New) A molecule which (a) comprises SEQ ID NO:7; and (b) is a single chain Fv.

81. (New) The molecule of claim 80 which is conjugated to a chemotherapeutic agent.

82. (New) The molecule of claim 69 or 71 which comprises SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.

83. (New) A protein comprising an amino acid sequence that comprises regions having at least 80% identity to SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, respectively, as determined by use of the BLASTp computer program, which protein (a) binds CD40; and (b) is a single chain Fv.

84. (New) The molecule of claim 83 which comprises which comprises SEQ ID NO:8, SEQ ID NO:9, or SEQ ID NO:10.

85. (New) The molecule of claim 83 which comprises at least 2 CDR sequences selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO 10.

86. (New) A molecule which (a) competes for binding to CD40 with monoclonal antibody S2C6 as secreted by the hybridoma deposited with the ATCC and assigned accession number PTA-110; (b) comprises at least 2 CDR sequences selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO 10; and (c) comprises a human immunoglobulin constant domain.

87. (New) The molecule of claim 86 which is an antibody.

88. (New) The molecule of claim 86 or 87 which comprises SEQ ID NO:8 and SEQ ID NO:10.